Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: Role of CD4+ and CD8+ T cells

Vaccine

Volumn 28, Issue 46, 2010, Pages 7414-7419

  Limon Flores, Alberto Yairh ^a   Cervera Cetina, Rodrigo ^a   Tzec Arjona, Juan L ^a   Ek Macias, Lorena ^a   Sánchez Burgos, Gilma ^b   Ramirez Sierra, Maria J ^a   Cruz Chan, J Vladimir ^a   VanWynsberghe, Nicole R ^a   Dumonteil, Eric ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c TULANE UNIVERSITY   (United States)

Author keywords

Chagas disease; DNA vaccine; Immunotherapy

Indexed keywords

ALUMINUM PHOSPHATE; DNA VACCINE; GAMMA INTERFERON; PARASITE ANTIGEN; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INFLAMMATION; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

EID: 77958194026     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.104     Document Type: Article

References (46)

1. Reithinger R., Tarleton R.L., Urbina J.A., Kitron U., Gurtler R.E. Eliminating Chagas disease: challenges and a roadmap. BMJ 2009, 338:b1283.
2. Dumonteil E. Update on Chagas' disease in Mexico. Salud Publica Mex 1999, 41:322-327.
3. Dias J.C., Silveira A.C., Schofield C.J. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002, 97(5):603-612.
4. Schofield C.J., Jannin J., Salvatella R. The future of Chagas disease control. Trends Parasitol 2006, 22:583-588.
5. Castro J.A., de Mecca M.M., Bartel L.C. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006, 25(August (8)):471-479.
6. Tarleton R.L., Reithinger R., Urbina J.A., Kitron U., Gurtler R.E. The challenges of Chagas Disease-grim outlook or glimmer of hope. PLoS Med 2007, 4(December (12)):e332.
7. Tarleton R.L. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001, 31(5-6):550-554.
8. Hyland K.V., Leon J.S., Daniels M.D., Giafis N., Woods L.M., Bahk T.J., et al. Modulation of autoimmunity by treatment of an infectious disease. Infect Immun 2007, 75(July (7)):3641-3650.
9. Marin-Neto J.A., Cunha-Neto E., Maciel B.C., Simoes M.V. Pathogenesis of chronic Chagas heart disease. Circulation 2007, 115(March (9)):1109-1123.
10. Dumonteil E. DNA vaccines against protozoan parasites: opportunities and challenges. J Biomed Biotechnol 2007, 2007:90520.
11. Dumonteil E. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 2009, 9(December (6)):1075-1082.
12. Silveira E.L., Claser C., Haolla F.A., Zanella L.G., Rodrigues M.M. Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease. Clin Vaccine Immunol 2008, 15(August (8)):1292-1300.
13. Bhatia V., Garg N.J. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol 2008, 15(June (8)):1158-1164.
14. Fralish B.H., Tarleton R.L. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine 2003, 21(June (21-22)):3070-3080.
15. Wizel B., Garg N., Tarleton R.L. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun 1998, 66(11):5073-5081.
16. Tzelepis F., de Alencar B.C., Penido M.L., Gazzinelli R.T., Persechini P.M., Rodrigues M.M. Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. Infect Immun 2006, 74(April (4)):2477-2481.
17. Miyahira Y., Takashima Y., Kobayashi S., Matsumoto Y., Takeuchi T., Ohyanagi-Hara M., et al. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 2005, 73(November (11)):7356-7365.
18. Araujo A.F., de Alencar B.C., Vasconcelos J.R., Hiyane M.I., Marinho C.R., Penido M.L., et al. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 2005, 73(September (9)):6017-6025.
19. Martin D.L., Weatherly D.B., Laucella S.A., Cabinian M.A., Crim M.T., Sullivan S., et al. CD8+ T-cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006, 2(August (8)):e77.
20. Dumonteil E., Escobedo-Ortegon J., Reyes-Rodriguez N., Ramirez-Sierra M.J., Arjona-Torres A. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun 2004, 72(1):46-53.
21. Sanchez-Burgos G., Mezquita-Vega G., Escobedo-Ortegon J., Ramirez-Sierra M.J., Arjona-Torres A., Rodrigues M.M., et al. Comparative efficacy of DNA vaccines encoding various Trypanosoma cruzi antigens. FEMS Microbiol Med Immunol 2007, 50:333-341.
22. Zapata-Estrella H., Hummel-Newell C., Sanchez-Burgos G., Escobedo-Ortegon J., Ramirez-Sierra M.J., Arjona-Torres A., et al. Control of Trypanosoma cruzi infection and changes in T cell populations induced by a therapeutic DNA vaccine in mice. Immunol Lett 2006, 103(2):186-191.
23. Sun J., Tarleton R.L. Predominance of CD8+ T lymphocytes in the inflammatory lesions of mice with acute Trypanosoma cruzi infection. Am J Trop Med Hyg 1993, 48(February (2)):161-169.
24. Ben Younes-Chennoufi A., Said G., Eisen H., Durand A., Hontebeyrie-Joskowicz M. Cellular immunity to Trypanosoma cruzi is mediated by helper T cells (CD4+). Trans R Soc Trop Med Hyg 1988, 82(1):84-89.
25. Sato M.N., Yamashiro-Kanashiro E.H., Tanji M.M., Kaneno R., Higuchi M.L., Duarte A.J. CD8+ cells and natural cytotoxic activity among spleen, blood, and heart lymphocytes during the acute phase of Trypanosoma cruzi infection in rats. Infect Immun 1992, 60(March (3)):1024-1030.
26. Fuenmayor C., Higuchi M.L., Carrasco H., Parada H., Gutierrez P., Aiello V., et al. Acute Chagas' disease: immunohistochemical characteristics of T cell infiltrate and its relationship with T. cruzi parasitic antigens. Acta Cardiol 2005, 60(February (1)):33-37.
27. Higuchi Mde L., Gutierrez P.S., Aiello V.D., Palomino S., Bocchi E., Kalil J., et al. Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process. Virchows Arch A Pathol Anat Histopathol 1993, 423(3):157-160.
28. Reis D.D., Jones E.M., Tostes S., Lopes E.R., Gazzinelli G., Colley D.G., et al. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A+ CD8+ lymphocytes. Am J Trop Med Hyg 1993, 48(May (5)):637-644.
29. Bosseno M.F., Espinoza B., Sanchez B., Breniere S.F. Mexican Trypanosoma cruzi stocks: analysis of minicircle kDNA homologies by cross-hybridization. Mem Inst Oswaldo Cruz 2000, 95(4):473-476.
30. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donnelly J.J., McClements W.L., et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 1999, 18:18-28.
31. Rosado-Vallado M., Mut-Martin M., Garcia-Miss M.R., Dumonteil E. Aluminium phosphate potentiates DNA vaccines against Leishmania mexicana. Vaccine 2005, 23(46-47):5372-5379.
32. Caliari M.V., De Lana M., Caja R.A., Carneiro C.M., Bahia M.T., Santos C.A., et al. Immunohistochemical studies in acute and chronic canine chagasic cardiomyopathy. Virchows Arch 2002, 441(1):69-76.
33. Rodrigues M.M., de Alencar B.C., Claser C., Tzelepis F., Silveira E.L., Haolla F.A., et al. Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice. Mem Inst Oswaldo Cruz 2009, 104(July (Suppl. 1)):281-287.
34. Duthie M.S., Kahn M., Zakayan A., White M., Kahn S.J. Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection. Clin Vaccine Immunol 2007, 14(May (8)):1005-1012.
35. Haolla F.A., Claser C., de Alencar B.C., Tzelepis F., de Vasconcelos J.R., de Oliveira G., et al. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection. Vaccine 2009, 27(September (41)):5644-5653.
36. de Alencar B.C., Araujo A.F., Penido M.L., Gazzinelli R.T., Rodrigues M.M. Cross-priming of long lived protective CD8+ T cells against Trypanosoma cruzi infection: importance of a TLR9 agonist and CD4+ T cells. Vaccine 2007, 25(August (32)):6018-6027.
37. de Alencar B.C., Persechini P.M., Haolla F.A., de Oliveira G., Silverio J.C., Lannes-Vieira J., et al. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 2009, 77(October (10)):4383-4395.
38. Martin D., Tarleton R. Generation, specificity, and function of CD8 T cells in Trypanosoma cruzi infection. Immunol Rev 2004, 201(October):304-317.
39. Hoft D.F., Eickhoff C.S., Giddings O.K., Vasconcelos J.R., Rodrigues M.M. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol 2007, 179(November (10)):6889-6900.
40. Padilla A.M., Bustamante J.M., Tarleton R.L. CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol 2009, 21(August (4)):385-390.
41. Tzelepis F., de Alencar B.C., Penido M.L., Claser C., Machado A.V., Bruna-Romero O., et al. Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance. J Immunol 2008, 180(February (3)):1737-1748.
42. Rottenberg M.E., Bakhiet M., Olsson T., Kristensson K., Mak T., Wigzell H., et al. Differential susceptibilities of mice genomically deleted of CD4 and CD8 to infections with Trypanosoma cruzi or Trypanosoma brucei. Infect Immun 1993, 61(December (12)):5129-5133.
43. Tarleton R.L., Koller B.H., Latour A., Postan M. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 1992, 356:338-340.
44. Padilla A., Xu D., Martin D., Tarleton R. Limited role for CD4+ T-cell help in the initial priming of Trypanosoma cruzi-specific CD8+ T cells. Infect Immun 2007, 75(January (1)):231-235.
45. Chou B., Hiromatsu K., Hisaeda H., Duan X., Imai T., Murata S., et al. Genetic immunization based on the ubiquitin-fusion degradation pathway against Trypanosoma cruzi. Biochem Biophys Res Commun 2010, 392(February (3)):277-282.
46. Chou B., Hisaeda H., Shen J., Duan X., Imai T., Tu L., et al. Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein. Microbes Infect 2008, 10(March (3)):241-250.